Science News
Transforming Scientific Review: PagePeek’s AI Evaluation for Molecular Dynamics Research
Molecular dynamics simulation has emerged as a crucial bridge between theoretical understanding and experimental observation in molecular science. Spanning physics, chemistry, biology, and materials science, MD research requires sophisticated evaluation that encompasses force field accuracy, sampling adequacy, statistical analysis, and biological or materials relevance. PagePeek leverages cutting-edge AI technologies including trajectory analysis neural networks, force field optimization algorithms, and protein structure prediction models to provide comprehensive paper assessment that recognizes molecular dynamics' unique position as both computational method and scientific discovery tool, employing machine learning trained on simulation databases to evaluate research for technical rigor, methodological validity, and scientific insight across diverse applications from protein folding to materials design. PagePeek's AI-driven paper evaluation framework for molecular dynamics begins with force field selection and validation, utilizing deep learning models trained on force field performance data and quantum mechanical calculations. The system's neural networks examine whether force fields are appropriate for the systems studied, whether parameters are properly derived or justified for non-standard molecules through automated parameterization assessment, and whether force field limitations are acknowledged. Machine learning algorithms evaluate whether papers combining quantum mechanics with molecular mechanics (QM/MM) properly define boundaries and coupling schemes, whether polarizable force fields are used when electronic polarization is important, and whether coarse-grained models maintain essential physics while achieving computational efficiency. The AI Professor engine, powered by predictive models and validation algorithms, particularly scrutinizes whether force field choices are validated against experimental data relevant to the properties being studied. The evaluation framework emphasizes reproducibility and computational transparency. PagePeek examines whether simulation input files are provided or repositories cited, whether analysis protocols are described with sufficient detail, and whether software versions and hardware specifications are reported. It evaluates whether custom analysis code is made available, whether trajectories are deposited in appropriate databases, and whether figures accurately represent statistical distributions rather than cherry-picked configurations. These criteria align closely with recent reproducibility guidelines proposed in Communications Biology ( Reliability and reproducibility checklist for molecular dynamics simulations , 2023, Nature Communications Biology , 6:268), which highlight the importance of convergence validation, methodological transparency, and open data sharing in molecular dynamics research. For simulation protocol evaluation, PagePeek reviews system preparation and equilibration procedures with precision. It checks whether initial structures include correct protonation states, solvation layers, and realistic ion concentrations. The system verifies that equilibration protocols effectively relax initial configurations, that pressure and temperature controls are appropriate, and that boundary conditions and long-range electrostatics are handled correctly. It particularly values studies demonstrating property convergence during equilibration. In assessing sampling and convergence, PagePeek applies strict statistical standards. It determines whether simulation timescales sufficiently capture relevant conformations, whether multiple runs confirm reproducibility, and whether enhanced sampling methods are properly implemented when required. The system evaluates free energy calculations for error analysis, rare-event sampling adequacy, and convergence across multiple metrics. Recognizing that properties converge at different rates, it ensures conclusions are supported by statistically robust sampling. For protein dynamics studies, PagePeek provides specialized evaluation reflecting biomolecular complexity. It checks whether simulations capture functional motions, analyze allosteric mechanisms accurately, and use reliable free energy methods for ligand binding. The system assesses whether protein flexibility is considered in drug design, whether ensembles are validated against NMR or experimental data, and whether limitations of classical force fields—such as in proton transfer or metal coordination—are properly acknowledged. In nucleic acid simulations, PagePeek evaluates both force field accuracy and sampling depth for DNA and RNA. It examines whether base pairing and stacking interactions are well represented, ion distributions are realistic, and structural parameters align with experimental data. The system also checks whether DNA–protein interaction studies distinguish specific from non-specific binding, whether RNA folding simulations reach native states, and whether modified nucleotides are accurately parameterized. PagePeek provides advanced evaluation for membrane and lipid simulations. It checks whether membrane compositions reflect biological complexity, simulations reproduce correct lipid phase behavior, and protein–membrane interactions maintain both structural integrity and function. The system also verifies that transmembrane voltage simulations apply electric fields correctly, lipid diffusion and flip-flop rates are realistic, and membrane protein models include adequate lipid diversity rather than single-component bilayers. In materials science applications, PagePeek assesses molecular dynamics studies of polymers, interfaces, and nanomaterials. It evaluates whether polymer simulations reach equilibrium despite long relaxation times, interface models capture accurate surface chemistry and structure, and nanoparticle simulations reflect size-dependent effects. The system reviews whether predicted mechanical and transport properties align with experimental data and whether self-assembly simulations achieve thermodynamic, not kinetically trapped, structures. Evaluation of enhanced sampling methods highlights PagePeek’s methodological depth. It examines whether collective variables in metadynamics or umbrella sampling define reaction coordinates properly, whether replica exchange simulations ensure adequate mixing, and whether adaptive biasing explores phase space effectively. The system checks free energy surface convergence, preservation of symmetry, accurate extraction of kinetic information, and validation of biased results against unbiased references. PagePeek excels in evaluating molecular dynamics studies that cross scales and disciplines. It reviews papers combining MD with experiments for both computational rigor and integration quality, assesses systems biology applications for atomic accuracy and biological relevance, and evaluates ML-based studies for algorithmic innovation and physical insight. The system identifies when molecular detail is essential for mechanism discovery or when simplified models suffice. The framework emphasizes reproducibility and computational transparency. PagePeek checks whether simulation inputs and repositories are shared, analysis protocols clearly described, and software versions reported. It ensures custom code is accessible, trajectories stored in public databases, and figures represent statistical distributions rather than selective snapshots. For method development studies, PagePeek evaluates both theoretical soundness and implementation quality. It verifies whether new algorithms are properly derived, validated, and benchmarked, whether efficiency improvements are demonstrated fairly, and whether implementations are publicly available. The system ensures methods are tested on diverse systems, numerically stable, and clearly defined in scope and limitations. Given water’s central role in biomolecular simulations, PagePeek pays particular attention to water model selection and validation. It checks whether models suit the studied properties, whether trade-offs between accuracy and efficiency are acknowledged, and whether conclusions depend on model-specific artifacts. The system ensures simulations demanding high water accuracy use proper models, hydrophobic effects are correctly represented, and ion parameters remain compatible. PagePeek serves the entire molecular dynamics community — providing reviewers with fast technical assessments, helping experimentalists identify validated simulations, guiding developers on innovation and usability, and teaching students the standards of rigorous computational research. As molecular dynamics expands toward larger systems, longer timescales, and new domains through better algorithms and hardware, PagePeek upholds rigorous yet adaptable evaluation standards. Balancing precision with practicality, it advances molecular dynamics as a cornerstone for understanding molecular mechanisms across chemistry, biology, and materials science.
PagePeek : AI-Powered Paper Evaluation and Quality Assessment Transforming Interdisciplinary Materials Science
New Glycan Microarray Assay from CD BioGlyco Aims to Solve Long-Standing Analytical Challenge
Government Lab Enterprises Focuses On Enhancing Lab Safety Through Innovative Furniture Designs
- September 23, 2025Science
Sustainably Stylish: Malaysia’s 4tify Brings Lab-Grown Leather, Biomaterials to the World
The production of biomaterials – including bio-vegan textile auxiliaries and bioleather – by 4tify Sdn Bhd is projected to generate an annual turnover of USD20 million starting in 2026 through local and international distribution. The BioNexus Status company is scaling up its operations to tackle global textile and fashion waste while driving Malaysia’s bioeconomy forward with biodegradable and recyclable materials powered by biotechnology and bioprocess engineering. This expansion supports sustainable and circular practices in Malaysia’s textile, leather, and industrial sectors by converting low-value agricultural residues into high-value sustainable biomaterials. In doing so, 4tify helps reduce waste and carbon emissions while creating a new industrial sub-sector for the nation. 4tify’s expansion is also expected to reduce imports and drive exports to markets including the European Union, Japan, and the United States. The Minister of Science, Technology and Innovation, YB Tuan Chang Lih Kang, welcomed 4tify’s progress in developing and scaling bio-based auxiliaries and microbial bioleather. He noted that the company’s technologies could cut carbon emissions by up to 61,500 metric tonnes annually across textile finishing and the leather industry by 2027, while advancing the circular economy and reducing reliance on imported petrochemical-based chemicals. He added that 4tify’s journey – from an early-stage startup under Bioeconomy Corporation’s Bio-based Accelerator (BBA) programme to a full-fledged BioNexus Status company – reflects the government’s mission to transform Malaysia into a high-technology and sustainable nation by 2030. “4tify is a national showcase of Malaysia’s strength to advance from research and development to full-scale industrial bio-manufacturing. By producing cost-competitive, sustainable alternatives to petroleum-based materials, 4tify is positioning Malaysia at the forefront of global biomaterials innovation while creating new high-value skilled jobs such as bioprocess engineers, QC specialists, and production scientists. We are weaving sustainability not only in style, but also in the heart of our economy and the fabric of our society,” said Chang during his visit to 4tify’s facility in Penang. Also present were Bioeconomy Corporation Chief Executive Officer, Encik Mohd Khairul Fidzal Abdul Razak, and 4tify Chief Executive Officer, Stan Kam. Mohd Khairul emphasised that Bioeconomy Corporation has been instrumental in nurturing 4tify’s growth as one of its investee companies, providing technical facilitation, market validation, and strategic support, which has enabled the company to innovate and expand its sustainable practices in the bioeconomy sector. “With a target to reach 8 million kilograms of bio-based auxiliaries and 100,000 square feet of bioleather annually by 2027, 4tify is on track to become the leading global producer in its field. Bioeconomy Corporation will continue to support this ambition by facilitating access to investors, R&D institutes, and international markets, ensuring 4tify can scale production to meet rising export demand from global fashion and textile brands. We are excited to be part of 4tify’s journey to redefine sustainable fashion and textiles, while elevating Malaysia’s profile as a global hub for biomaterials innovation,” he said. 4tify has earned international recognition as one of the Top 5 plant-based startups, with accolades from StartUs USA and selection into the Y Combinator Startup School 2017/2018 batch. The company’s innovations are also featured in the Plug & Play USA Sustainable Fashion Playbook, underscoring its leadership in advancing sustainable fashion solutions. 4tify’s initiatives are closely aligned with the National Biotechnology Policy 2.0, particularly the thrust on Industrial Biotechnology and Circular Economy. This initiative also supports MOSTI’s National Science, Technology and Innovation Policy (NSTIP) 2021–2030, which prioritises future-focused, sustainable industries.
- September 16, 2025Science
From Bench to Breakthrough: Creative Biolabs Accelerates Immune-Based Discoveries
Due to the ever-increasing number of requests for precision tools used in immunotherapy research, Creative Biolabs has responded by launching a suite of advanced product options to support and strengthen the development of next-generation immune-based therapies. Hemolysis Assay for Solutes: A New Benchmark for Complement Activation Study Complement activation is a key safety and efficacy process for therapeutic agents, in particular, unwanted immune responses associated with monoclonal antibodies, liposomes, and nanoparticles. Creative Biolabs' hemolysis assay for solutes demonstrates a versatile and cost-effective preclinical 2×96-well high-throughput format hemolysis assay for assessing complement-mediated hemolysis across multiple species. It is an excellent option for screening solutes that trigger unwanted immune responses, providing hematology researchers with reliable hemolysis data to pursue formulating and dosing adjustments. Double Emulsion Droplet Chip: Microfluidics for Precision Encapsulation Microfluidic technologies are changing how scientists are able to manipulate cells, reagents, and biomolecules at the microscale. The double emulsion droplet chip from Creative Biolabs uses a flow-focusing design and localized surface modifications to create double emulsion droplets with a very uniform structure. "The chip is made from glass for durability, and it is also able to function at high pressure and at high temperatures, allowing it to be used to encapsulate immune cells, build microreactors, and facilitate single-cell assays. The chip nozzle sizes can be customized; it also works with many surfactants." So researchers can use this technology to offer control and reproducibility that enables the investigation of novel drug delivery models, synthetic biology systems, and cell-based assays. Human Alveolar Macrophages: A Physiology-Relevant Model of Innate Immunity Understanding how macrophages participate in immune regulation, inflammation, and tissue homeostasis is a crucial aspect of developing effective immunotherapies. So, they now offer isolated human alveolar macrophages . These cells are isolated from the lungs of healthy donors and pathogen-tested. "Researchers are paying more and more attention to human alveolar macrophages in developing new treatments. They're being used in things like drug delivery and immune system therapies, which could really help fight serious lung infections and boost overall lung health," said a scientist. Driving Innovation in Immunotherapy Research The new product line reflects their commitment to empowering researchers using scientifically independent, human-relevant, and engineered solutions, which will enable researchers to develop therapeutics faster, safer, and more effectively. For detailed product and custom services information, visit https://www.creative-biolabs.com/complement-therapeutics/. About Creative Biolabs Creative Biolabs is dedicated to improving immunotherapy research and exploring innovative technologies to enable deeper discovery, greater experimental precision, and increased speed-to-discovery for the immune sciences.
- September 10, 2025Science
2025 Removable Metal Floor Panels Market Analysis and Forecast Report-PW Consulting
PW Consulting has published a comprehensive research report focusing on the Removable Metal Floor Panels Market, a sector pivotal to the evolution and modernization of commercial, industrial, and data center environments. This report aims to provide stakeholders, including manufacturers, architects, contractors, and end-users, with clear insights into the multifaceted landscape of removable metal floor panel solutions. The depth of the research in this report is underscored by its extensive scope, covering market segmentation, technological advancements, supply chain analysis, end-use applications, competitive landscape, and emerging trends that are shaping the industry in 2025. The first core element in the PW Consulting report is an elaborate market segmentation. The study categorizes removable metal floor panels by type, material, application, installation method, and regional adoption. Under type, the report distinguishes between steel, aluminum, and hybrid metal panels, examining the advantages each material brings, such as durability, load-bearing capacity, and weight reduction. For instance, aluminum panels are particularly highlighted for retrofitting aging facilities where lightweight solutions are critical. The segmentation by installation method covers both screw-down and snap-in systems, reflecting evolving preferences among installation professionals seeking speed and flexibility in different environments. On the applications front, the report delves deeply into how removable metal floor panels have found favor in diverse sectors. Key industries covered include office buildings, server rooms, cleanrooms, educational facilities, transportation hubs, and healthcare institutions. The study emphasizes the growing use of these panels in data centers, a trend attributed to the exponential increase in global data generation, digitization, and the demand for efficient cable management and air distribution. Experts featured in the report note the importance of the flexibility offered by removable systems for fast reorganization of floor layouts, which has become critically important in industries that value adaptability and minimal downtime. In its materials and product advancements segment, the PW Consulting report investigates how R&D is shaping new product offerings. With sustainability at the forefront of decision-making processes, the study highlights innovations such as recycled metal usage, low-carbon production techniques, and surface coatings that enhance corrosion resistance and support cleaner indoor environments. Experts interviewed for the report underline the increasing pressure on suppliers to comply with green building standards and certification schemes. Several leading brands are showcased for their commitment to Environmental Product Declarations (EPDs) and their investment in circular economy models. The report also delivers an in-depth technology and manufacturing analysis, profiling leading manufacturing methods including stamping, welding, and advanced assembly techniques to create panels that meet a range of static and dynamic load requirements. The incorporation of IoT-ready sensors in select solutions is given significant attention, revealing how the market is responding to smart building trends. These sensors allow facility managers to track temperature, humidity, or even foot traffic, helping to optimize energy consumption and maintenance schedules. PW Consulting’s market experts discuss how seamless integration with building management systems (BMS) is a strong value proposition for high-end users in corporate and mission-critical environments. A thorough supply chain assessment is a central component of the report, mapping the relationships between raw material suppliers, panel manufacturers, distribution networks, and end-users. This analysis covers current trends in supply chain resilience, the impact of regional supply disruptions, and adaptive strategies implemented by leading players to mitigate risks. Being a post-pandemic era study, the report places special emphasis on the lessons learned from supply interruptions in 2020–2022, focusing on diversification of sources and the acceleration of nearshoring activities within major economic blocs, particularly in North America and Europe. The competitive landscape section provides a detailed overview of major and emerging players in the removable metal floor panel market. This includes company profiles, product portfolios, recent innovations, partnerships, and mergers and acquisitions activity observed in the previous 24 months. PW Consulting’s analysts examine the strategic initiatives taken by both international conglomerates and regional specialists to strengthen their market positions, with a focus on differentiation through customization capabilities, sustainability credentials, and digital service offerings. The report highlights how start-ups are leveraging digital platforms and e-commerce to penetrate traditionally siloed construction supply chains, disrupting established market hierarchies. The regulatory environment and compliance landscape is another focal area of the PW Consulting report. The research covers prevailing international standards such as ISO, EN, and ASTM, as well as the implications of strict local building codes on product design and fire safety certifications. Interviews with compliance officers provide an overview of the evolving requirements for non-combustibility, electromagnetic shielding, and anti-static properties—factors particularly influential in healthcare and data-sensitive environments. The study draws attention to ongoing regulatory shifts linked to sustainability, such as the use of traceable materials and mandatory material disclosures in green building projects. From a regional perspective, the study analyzes demand drivers and adoption barriers across the Americas, Europe, the Asia-Pacific, the Middle East, and Africa. It discusses the influence of macroeconomic factors—such as urbanization rates, infrastructure investments, and industrial automation trends—on the adoption of removable metal floor panels. The report identifies areas, particularly in Southeast Asia and the Middle East, where rapid expansion of commercial real estate and government initiatives for smart cities are opening new avenues for market participants. Emerging trends constitute a special feature in the PW Consulting report. One highlighted trend is the growing use of Building Information Modeling (BIM) for the customization and planning of raised flooring solutions. The study notes how BIM integration is becoming a critical requirement for collaboration among architects, designers, and facility managers, helping to reduce project lead times and coordinate lifecycle assessments. Another trend involves multi-functionality, with new panel solutions offering underfloor heating, sound attenuation, and modularity for plug-and-play technology integration, meeting the needs of “future-proof” building design. The demand drivers and inhibitors section of the report breaks down the key short-term and long-term influences impacting the removable metal floor panel market. The accelerating transformation toward hybrid workplaces and the expansion of e-commerce distribution centers are marked as significant contributors to installation activity. Conversely, the report documents challenges such as cost pressures on capital projects, competition from alternative flooring materials, and the slow pace of regulatory harmonization in emerging economies. Strategic recommendations from PW Consulting suggest active monitoring of these inhibitors and the adoption of agile market entry strategies. To aid strategic planning, the report includes a SWOT analysis and Porter’s Five Forces evaluation, enabling readers to gauge bargaining power among suppliers and buyers, the threat of new entrants, the risk of substitute products, and the intensity of industry rivalry. Industry executives are provided with actionable insights to position their organizations effectively, exploit new opportunities, and avoid pitfalls in a competitive and fast-evolving market environment. In summary, the PW Consulting report on the Removable Metal Floor Panels Market in 2025 serves as an indispensable resource for industry participants. Its rigorous examination of market segmentation, end-use scenarios, supply chain adaptation, technical innovation, and regulatory evolution offers a rounded view of both present realities and the future trajectory for this dynamic and critical sector. It equips stakeholders with the actionable intelligence required to make informed strategic, operational, and financial decisions in a marketplace that is increasingly defined by flexibility, sustainability, and smarter infrastructure solutions.
- September 9, 2025Science
Cutting-Edge Antibody Validation Service by Boster Bio Set to Enhance Research Accuracy
Boster Biological Technology (Boster Bio), a leading provider of antibody and immunoassay solutions, is revolutionizing biomedical research with its antibody validation service and IHC services . These offerings ensure researchers receive rigorously tested, high-quality reagents, addressing a critical need for reproducibility in scientific studies. A major challenge in life sciences research is the inconsistent performance of antibodies, which can lead to unreliable data. Boster Bio’s antibody validation service tackles this issue head-on by employing a multi-step verification process. Each antibody undergoes specificity, sensitivity, and reproducibility testing across multiple applications, including Western blot, ELISA, and immunohistochemistry (IHC). What sets Boster Bio apart is its commitment to transparency. Researchers receive comprehensive validation reports, including detailed experimental conditions and raw data. This level of scrutiny ensures that antibodies perform as expected, reducing wasted time and resources. A unique industry advantage, the company also offers a free validation for the PicoBand antibodies promotion, allowing scientists to test antibodies before purchase. In addition to antibody validation, Boster Bio offers specialized IHC services, catering to researchers who require high-quality immunohistochemistry without needing in-house optimization. The company’s histology experts handle everything from tissue sectioning to staining, using validated protocols to deliver consistent, publication-ready results. Boster Bio’s IHC services stand out due to their customization options. Researchers can request specific antibodies, staining techniques, or tissue types, ensuring tailored solutions for unique projects. The team also offers troubleshooting support, a critical resource for complex studies. With increasing scrutiny on research reproducibility, Boster Bio’s emphasis on validation and quality control fills a crucial gap. Besides the free antibody validation for select products, the company provides comprehensive IHC services with expert support, including transparent reporting and their accompanying raw data. For more information, visit https://www.bosterbio.com/ A leading antibody manufacturer since 1993, Boster Bio combines scientific excellence and customer-focused solutions. Dedicated to advancing biomedical research, the company delivers rigorously validated reagents and expert support to scientists worldwide. This empowers researchers to achieve accurate, reproducible results that can accelerate discoveries in immunology, oncology, and neuroscience. The service to validate antibodies for IHC, WB, ELISA, IF/ICC, or flow cytometry experiments is crucial in today’s fast-developing biotech sector. Boster Bio's experts accelerate research efforts by providing over 200 ready-to-use control samples available for validation. Whether validating antibodies generated in-house or procured commercially, the validation process can be time-consuming, expensive, and frustrating. As an antibody manufacturer, Boster Bio addresses this issue by leveraging its economies of scale and close relationships with other antibody companies. With fast turnaround empowered by scale and expertise, the company readily accommodates custom requirements cost-effectively and efficiently. Additionally, Boster Bio assigns a dedicated project manager from start to finish. The company also offers a large selection of ready-to-use cell lines and tissue lysates for your assay controls. Compared to acquiring these in-house, using commercially available lysates could save months of cell culture work and related expenses. Boster Biological Technology is a leading provider of high-quality antibodies, ELISA kits, and custom assay services. Specializing in antibody validation and IHC services, the company ensures research accuracy with stringent quality controls and transparent reporting. Based in Pleasanton, CA, Boster Bio supports scientists in immunology, oncology, and neuroscience with reliable reagents and expert technical assistance. Its unique offerings, including free antibody validation and tailored immunohistochemistry solutions, set it apart in the competitive life sciences market. Committed to accelerating discoveries, Boster Bio empowers researchers with trusted tools for reproducible, publication-ready results. About the Company: Boster Bio is a leading manufacturer of antibodies and ELISA kits critical to advancing life science research. Specializing in custom monoclonal antibody production services and offering free antibody validation, the company supports researchers with high-quality reagents and exceptional service. Based in Pleasanton, CA, Boster Bio continues to innovate in antibody development and immunoassay solutions.
- August 27, 2025Science
Shaping the Science of Beauty With Exosomes—Insights from Creative Biolabs
Exosomes are generated from the processes of cells and have recently transitioned from fundamental science to clinics and the consumer world. Aesthetics and plastic surgery are perhaps the most exciting opportunities among these possibilities. In this context, Creative Biolabs is actively driving the development and application of exosome cosmetics by utilizing its proficiency in exosome engineering and research. Unlike conventional cosmetic ingredients, exosomes mimic the body's natural communication mechanisms, providing a gentler, more efficient, and highly targeted approach. "Exosomes are not just 'active ingredients'; they are tiny 'data' carriers loaded with a variety of signaling molecules," one of the company's experts stated in a recent interview. Their ability to regulate skin regeneration, reduce inflammation, and promote collagen synthesis can be far more efficient than traditional skincare methods." To support this rapidly evolving area, Creative Biolabs has set up a full range of customized solutions, from exosome isolation and purification, component analysis to quantitative detection and functional validation. Today, exosomes for skin care are becoming a hot topic in cosmetic product development. Exosomes can decrease fine wrinkles, improve texture, and revitalize the skin by boosting antioxidant capacity, stimulating fibroblasts, and strengthening the skin barrier. In addition, exosomes are being studied to provide longer-lasting cosmetic benefits by using engineered exosomes with greater delivery efficiency and stability. Through its customized advanced exosome engineering platforms, Creative Biolabs is capable of performing genetic changes, bioactive molecule loading, and release profile optimization, which helps clients to differentiate their products in the plastic and aesthetic surgery markets. Exosomes are no less significant in the field of plastic and aesthetic medicine. When combined with injectable therapies, exosomes may become valuable adjuncts for tissue repair. For instance, exosomes can be useful in the post-procedure recovery phase for minimally invasive treatments by accelerating cell regeneration and reducing inflammation. Creative Biolabs has already begun exploring this direction by offering tailored exosome solutions. Achieving industrial-scale applications still requires overcoming obstacles including reliable exosome isolation , purity, and safety validation. To address these, Creative Biolabs employs advanced isolation technologies, proteomic and nucleic acid profiling, and functional validation systems—ensuring reliability, traceability, and stability of the delivered results. The expert further acknowledged, "Every emerging technology faces the dual test of science and the marketplace. Our goal is to design exosome-based solutions for the cosmetic and aesthetic surgery industries that are more reliable and safer." About the Company With a wealth of experience in exosome engineering and applications, Creative Biolabs continues to expand the boundaries of this natural microscopic messenger, bringing new vitality to the pursuit of beauty and health.
- August 25, 2025Science
Creative Biolabs Drug Discovery Models: From 3D Tumor Spheroids to "Miniaturized Human Bodies" on a Chip
In the pursuit of new drugs and disease research, scientists are continuously pushing beyond the limitations of traditional cell assays and animal models, instead using innovative systems that more closely reflect human physiological states. 3D Tumor Spheroids : Restoring the Authenticity of the Microenvironment Conventional two-dimensional cell culturing remains ubiquitous for its ease, yet it fails to represent the intricate cell interactions in a three-dimensional context. In response, Creative Biolabs provides custom-engineered 3D tumor spheroid model services. These models more closely resemble the migration, proliferation, and treatment resistance of cancer cells by simulating the spatial structure and nutritional gradients of tumors in vitro . "If 2D cultures show us a 'single building,' then spheroid models reveal a 'miniature city,'" as one scientist at Creative Biolabs vividly explained. The expert team at Creative Biolabs has already applied different types of spheroid models to drug screening, target validation, and mechanism studies, helping researchers more accurately assess the potential of drug candidates in the preclinical stage. Creative Biolabs offers various constructed tumor spheroids, thereby catering to clients' specific requirements. * 3D Human Blood-Brain Barrier Spheroid Model * 3D Human Retinal Pigment Epithelial Spheroid Model * 3D Human Cortical Spheroid Model * 3D Hepatocyte-Stellate Cell Spheroid Model "Miniaturized Human Bodies" on a Chip If 3D spheroids represent the "micro-ecosystem" of tumor research, then Organ-on-a-Chip is the " in vitro human body" of drug development. In order to replicate the structure and capabilities of actual human organs, Creative Biolabs is extending its offerings in this field by using microfluidic technology to embed cells and tissues within chip platforms. The Disease-on-a-Chip model platforms developed by Creative Biolabs have already become indispensable tools for pharmaceutical companies to evaluate drug efficacy and safety. Among the various models * Lung-on-a-Chip can reconstruct gas exchange and airway inflammation. * Liver-on-a-Chip recreates metabolic activity and drug responses. * Gut-on-a-Chip reveals the dynamic interplay between microbes and host immunity. * Heart-Liver-Skin Three-Organ-on-a-Chip enables simultaneous observation of cardiac, hepatic, and skin responses in a connected microfluidic system. Chip-based systems exhibit great promise, particularly in medication safety evaluation and personalized medicine research, as they can produce more predictive outcomes faster than traditional animal models. As a result, more and more partners are choosing Creative Biolabs to integrate these models into their development pipelines, thereby improving efficiency and reducing the risk of failure. Organ-on-a-Chip and 3D spheroids are complementary tools rather than substitutes for one another. They are developing a multifaceted, multilayered research platform that offers preclinical studies more trustworthy evidence. The scientist summarized it well: "Drug discovery is moving toward greater precision and personalization. What we are doing is helping researchers bring laboratory experiments closer to the reality of human biology." For more cutting-edge solutions, visit https://www.creative-biolabs.com/3d-biology/. About Creative Biolabs Whether through customized 3D tumor spheroid models or comprehensive multi-organ chip platforms, Creative Biolabs delivers professional support to research teams worldwide.
- August 21, 2025Science
Creative Biolabs Initiates Complement Testing Solutions and Microfluidic Platforms
Creative Biolabs, the global leader in immunological assay development and microfluidic technology, is delighted to announce the expansion of its complement system testing portfolio by launching enhanced C1q binding test and C3b deposition assay services, as well as cutting-edge microfluidic platforms. The strategic integration offers unparalleled sensitivity, throughput, and custom-made solutions for researchers involved in immunotherapy, vaccine development, and autoimmune disease research. Creative Biolabs' complement C1q binding assay enables scientists to determine the complement activation potential of biologics, including monoclonal antibodies, Fc-fusion proteins, and antigen-antibody complexes. Being the classical complement pathway initiator, C1q is the key player in immune surveillance. Its binding activity needs to be characterized in order to predict complement-dependent cytotoxicity (CDC) and therapeutic safety profiles. They provide both ELISA-format and surface plasmon resonance (SPR) formats, which allow customers to choose between high-throughput screening or real-time kinetic profiling. With the provision of flexible ligand orientation, species customization, and the capacity for pairing with downstream complement assays (e.g., C3b, C4b, C5b-9), the service is tailored to suit a range of research needs. To augment the C1q assay, the C3b deposition assay quantitates the deposition of C3b on cell surfaces—a central event in amplifying the complement cascade. The assay is important in determining drug efficacy, dissecting disease mechanisms, and profiling immune evasion strategies. The simplified workflow of Creative Biolabs includes sample preparation, controlled complement activation, high-sensitivity detection by ELISA or flow cytometry, and professional data analysis. The clients receive comprehensive reports with quantitative data and statistical analysis, ensuring reproducibility and clarity. What makes Creative Biolabs an equally powerful partner in this field is its profound experience and proprietary technology in the field of microfluidics. Scientists can leverage Creative Biolabs' advanced lab-on-a-chip platforms for integrating sample handling, reaction control, and detection—all within miniature, customizable devices. Such microfluidic systems minimize reagent use and enable high-throughput analysis of numerous samples, significantly accelerating research without sacrificing analytical precision. By integrating immunological expertise with microfluidic engineering, Creative Biolabs allows scientists to develop deeper insights into complement biology more quickly and accurately. Whether you're developing next-generation biologics or investigating immune dysregulation, this integrated platform offers a scalable, customized solution that responds to the demands of modern biomedical research. For more information, please visit https://www.creative-biolabs.com/complement-therapeutics/. About Creative Biolabs Creative Biolabs is a global leading custom service biotechnology company, specialized in antibody engineering, immunoassay development, and microfluidics technology. From complement therapeutics to organ-on-a-chip, the company is committed to advancing science through precision, flexibility, and collaboration.
- August 14, 2025Science
Government Lab Enterprises Adds Ultra-Low Temperature Chest Freezer to Equipment Offerings
Government Lab Enterprises, a provider of durable, compliant, and adaptable laboratory furniture and equipment, has added the Arctiko SF150 -30°C to -60°C Chest Freezer to its equipment lineup. The 4.9 cu. Ft., 110V unit, is built to meet the stringent storage needs of temperature-sensitive materials across scientific and research laboratories. Known for supplying modular casework, epoxy resin countertops, fume hoods, sink bases, and mobile carts, Government Lab Enterprises serves a wide range of industries—including education, pharmaceuticals, biotechnology, and environmental science. The company emphasizes laboratory infrastructure that not only complies with regulatory requirements but also offers long-term durability and flexible workspace design. The addition of the Arctiko SF150 addresses a growing demand among clients for reliable cold storage in compact laboratory settings. As ultra-low temperature storage becomes increasingly critical for sample integrity, vaccine preservation, and long-term research, products like this chest arctiko freezer are a necessary component of modern lab environments. "Storage solutions must evolve alongside the scientific work they support," said a company spokesperson. "Integrating ultra-low temperature options such as Arctiko freezers ensures that our clients maintain the highest standards in biosample preservation and regulatory compliance." Designed for both function and efficiency, the Arctiko freezer supports temperatures as low as -60°C, making it suitable for applications requiring stringent thermal control. Its compact footprint enables it to fit seamlessly into laboratories where space is at a premium without compromising performance or reliability. This freezer joins a carefully curated selection of laboratory infrastructure products intended to streamline operations and support scientific discovery. Government Lab Enterprises maintains a focus on function-driven design, enabling research environments to remain organized, safe, and efficient. "As laboratories face increased demand for environmental control, our role is to support those needs with well-matched equipment and furnishings," the spokesperson added. "Arctiko freezers are a solid match for clients aiming to uphold both research precision and regulatory standards." Government Lab Enterprises continues to support laboratory innovation through product selections that emphasize operational effectiveness. By offering the Arctiko SF150 chest freezer, the company reinforces its role in equipping labs with trusted, compliant, and versatile solutions for their most sensitive materials.
- August 14, 2025Science
Yamaha Motor Begins Joint Research Using Cell Handling Technology with a national research institute - Advancing Next-Generation Automated Experimentation to Promote DX and AX in Research -
Yamaha Motor Co., Ltd. (Tokyo: 7272) announced today its signing of a joint research agreement with RIKEN, a National Research and Development Agency, regarding the application of next-generation cell handling and automation technologies using cell picking and imaging systems. This joint research aims to develop technologies and infrastructure that promote digital transformation (DX) and AI transformation (AX) in research settings. By combining the automation and analysis technology of the RIKEN Center for Biosystems Dynamics Research*¹ (BDR) with Yamaha Motor's cell observation and handling technologies, and utilizing AI, the goal is to standardize work, improve accuracy, and obtain highly reproducible data. The joint research project is scheduled to run from July 2025 to March 2027. This research will focus on developing APIs (Application Programming Interfaces) and data integration platforms that enable the coordination of research equipment software and programs, as well as advancing cell observation and handling technologies. In this collaboration, Yamaha Motor will implement the methodologies and designs developed by RIKEN BDR, and the two parties will work together to explore the social implementation of advanced cell experimentation. These efforts are expected to lead to outcomes such as the establishment of high-precision cell selection technologies, the realization of full automation, and the development of new research approaches through sophisticated cell handling. To meet diverse needs of life science research sites and the growing demands for automation, Yamaha Motor aims to gain further insights through this research to support future functional development and implementation. The Company also develops and provides systems designed for the high-speed, high-precision handling of cell clusters*² and acquisition of image data. These systems feature functions such as automatic cell selection and automatic stitching of surrounding images, aiming to enhance efficiency in research workflows and improve the reliability of collected data. *1 RIKEN Center for Biosystems Dynamics Research (RIKEN BDR): https://www.bdr.riken.jp/en/ *2 Cell clusters refer to single cells or 3D cellular structures such as spheroids and organoids.
- August 14, 2025Science
Fujifilm and HORIBA Co-developed Gene Delivery System to Enhance Productivity in Gene Therapy Manufacturing
FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) and HORIBA, Ltd. (President: Masayuki Adachi) today announced the co-development of a novel gene delivery system that significantly enhances productivity in the manufacture of gene therapy products. Fujifilm has developed the industry’s first*1 continuous electroporation technology*2, which enables high-efficiency gene delivery into cells during the manufacturing process for gene therapy products, boosting productivity by approximately 100 times*3 greater compared to conventional methods. HORIBA played a key role in integrating this technology into a system and plans to release the finalized device to the global market in 2026 or later. Gene therapy is an approach that uses biotechnology to introduce functional genes into the body, targeting the root cause of genetic disorders. This technology is attracting global attention for its potential in treating intractable diseases that currently lack effective treatment options. Although the global cell and gene therapy market is projected to grow at a compound annual growth rate of approximately 30% through to 2030*4, several challenges remain. These include overcoming the technological complexities and inefficiencies of current manufacturing processes as well as high costs associated with research and development. To address these challenges, Fujifilm and HORIBA, two companies with extensive expertise in the life sciences field, joined forces to develop a gene delivery system designed to enhance manufacturing productivity and reduce costs. The development process leveraged Fujifilm’s advanced technologies and process control expertise, honed across a broad range of business fields including biopharmaceuticals, while HORIBA contributed its extensive manufacturing expertise and global support capabilities for industrial applications to oversee the design and production of the system. Following its commercial launch, HORIBA will lead sales and support efforts, focusing on the North American and European markets, where demand for the gene therapy is particularly high. By combining their respective strengths to develop and roll out this system, Fujifilm and HORIBA aim to help solve the pressing societal challenge of unmet medical needs. Background of the Co-Development Project Fujifilm and HORIBA have a history of collaboration across a variety of fields, including bioscience and semiconductors. The two companies have previously engaged in joint research, including those using HORIBA’s sensor technologies to improve the efficiency of pharmaceutical production processes. In 2023, the two companies launched a joint project to develop a gene delivery system (continuous electroporation system) in order to address production challenges in the growing field of gene therapy products. The Continuous Electroporation System Overview of the Continuous Electroporation System In the manufacture of gene therapy products, which involves the introduction of genes into cultured cells, improving the efficiency of the gene delivery process is key to increasing overall productivity. The conventional method, which relies on chemical reactions transfection reagent, faces efficiency challenges due to the complex chemical reactions involved and the difficulty in controlling the interactions between cells and reagents. Fujifilm’s innovative continuous electroporation technology, which was utilized in the project, address these limitations. By applying precisely controlled electrical pulses to cell membranes, it creates minute pores that allow genes to be directly delivered into the cells, significantly enhancing gene delivery efficiency. Furthermore, the system operates in a continuous flow, offering flexibly to adjust throughput and handle production on both small to large-scale. Compared to conventional batch-based methods, this continuous electroporation system can achieve up to 100 times greater productivity, contributing substantially to both manufacturing efficiency and cost reduction in gene therapy production. Conventional Method Gene delivery performed using PEI*5 as a chemical transfection reagent Fujifilm’s Continuous Electroporation Technology Cells suspended in liquid are continuously passed through an electroporation unit where electrical pulses are applied, creating pores in the cell membranes via which genes can be injected directly Comment from Toshihisa Iida, Director, Corporate Vice President, General Manager of Life Sciences Strategy Headquarters At Fujifilm, we are dedicated to supporting pharmaceutical companies and patients through integrated solutions across the drug development lifecycle, guided by our "Partners for Life" principle. The implementation of continuous electroporation technology marks a major step forward, improving gene delivery efficiency while addressing manufacturing cost challenges. By combining Fujifilm's advanced technologies with Horiba's manufacturing expertise, we aim to create a future where gene therapy drugs are accessible to more patients. Through continuous innovation, we strive to advance healthcare and improve the well-being of people around the world. Comment from Masayuki Adachi, President of HORIBA I am delighted that we have succeeded in developing a continuous electroporation system based on Fujifilm’s outstanding technology. The Bio & Healthcare field is essential to future growth, and going forward we will leverage our strength in analytical and measurement technologies, data management capabilities, and global support infrastructure, which we have cultivated in high-volume manufacturing fields such as automotive products and semiconductors, to accelerate the commercialization of this system, thereby contributing to better health and quality of life for many people. *1 Based on research conducted by Fujifilm. *2 A technology that uses controlled electrical pulses to create minute pores in cell membranes, allowing genes to be directly delivered into cells. This enables high-efficiency gene delivery and is anticipated to enhance productivity while reducing costs in the manufacture of gene therapy products. This technology was presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy held in Los Angeles, U.S., in 2023. *3 Based on internal studies by Fujifilm. Compared to conventional chemical transfection using PEI reagents (as of August 7th, 2025). *4 Estimate by Fujifilm based on data provided by Evaluate Pharma®, January 2025. *5 PEI: Polyethylenimine, a type of polymeric material used as a reagent for delivering genes or proteins into cells. * Please note that the contents including the product availability, specification, prices and contacts in this website are current as of the date of the press announcement and may be subject to change without prior notice.
- August 11, 2025Science
Breaking Boundaries in Stroke Imaging: The World’s First Clinical CT with a Curved Detector
When we set out to design the Micro-X Head CT , our goal was simple: to bring stroke diagnosis to patients faster, whether in an ambulance, a rural clinic, or a hospital emergency bay. But achieving this meant rethinking how CT scanners work at a fundamental level. In conventional CT scanners, flat-panel detectors rotate around the patient on large gantries. These systems are incredibly effective but they’re also heavy, expensive, and mechanically complex. That makes them impractical for mobile environments where space, weight, and speed are critical. To build a system compact and lightweight enough for stroke diagnosis on the move, we needed to do something never done before: create a curved detector. Why Curved Matters With a curved detector, we could achieve wide angular coverage using a fixed gantry.That meant we could eliminate the need for heavy rotating parts while still capturing high-quality projection images from multiple angles. It was a breakthrough in reducing size, weight, and power requirements, making the Head CT faster, lighter, and more portable. But here’s the catch: there are no off-the-shelf curved X-ray detectors suitable for clinical CT imaging. Curved detectors have been explored in research or industrial uses (like inspecting pipelines), but not in medical imaging. So, we had to build one from scratch. Head CT under development Partnering for Innovation We partnered with FUJIFILM to co-develop a custom solution, leveraging their flexible scintillator substrate - the same material they use in their flat panel detectors. Our team worked closely with theirs to overlap two scintillators into a seamless curved array, paired with a dynamic readout system capable of capturing multiple exposures rapidly. This was crucial for integrating with our proprietary NEX technology and enabling fast reconstruction. With further refinement, we engineered a new version of the detector using FUJIFILM’s technology, redesigned by Micro-X to be even smaller and lighter to achieve a72% weight reduction from the initial prototype. That’s a huge win for mobility, especially when every gram counts in a portable CT system. Solving the Complex Challenges Introducing a curved detector came with its own imaging and mechanical hurdles. Traditional reconstruction algorithms weren’t built to handle curved geometry, leading to inconsistencies and image artifacts. So we teamed up with Johns Hopkins University who are experts in computational imaging to develop new methods that solve these problems head-on. Combined with Micro-X’s NEX technology, which precisely controls X-ray sources without mechanical motion, we’ve built a system that can acquire multiple projection images in rapid succession, all without a rotating gantry. The Micro-X Head CT for stroke diagnosis includes a world-first curved detector A World-First Achievement To our knowledge, the Micro-X Head CT is the first CT scanner designed for clinical use to feature a curved detector. It’s a major technical milestone - not just for us, but for the future of portable medical imaging. As an engineer, it’s been incredibly rewarding to push the boundaries of what’s possible in medical imaging. But what’s most meaningful is knowing this technology will have a real-world impact — transforming how and where people receive life-saving stroke care.
ALL NEWS
- Seacoat SCT Unveils Next-Generation Coating for Commercial Marine Hulls
- Green Tortoise Hostel Expands Weekly Programming with Structured Evening Activities
- Outsourced CFO Hosts Live LinkedIn Event: Supercharge Your Finance Function with Automation and AI
- Breaking Norms in Harlem, Real Estate: Trisha Paravas Sets New Standard for Middle-Market Luxury.
- Samanth Gurram Receives a 2025 Global Recognition Award for Excellence in Enterprise Data Architecture
- Revived Smiles Revolutionizes Dental Care with At-Home Partial Dentures
- Vintage City Maps Becomes Sole Source for Professionally Restored Historic Maps
- Insurance Pro Shop Redefines Agent Growth With Its Life Insurance Marketing System
- Insurance Pro Shop Advances Agent Career Growth with Comprehensive Training Pathways
- Scribe Security Launches Agentic AppSec Workflows to Tackle AI-Generated Code Risks
- LS Team Leads Humanitarian Relief Efforts in Earthquake-Stricken Cebu, Bringing Hope to Recovery
- Scribe Security Expands Global Reach with AI-Powered AppSec Agentic Workflows at Scale
- sbaloansHQ Launches Proprietary SBA Loan Brokerage Software Platform
- LS Team Leads Swift Relief Response After 6.9-Magnitude Earthquake Hits Cebu
- NoHarm Scents Debuts Humane Rodent Control Nationwide Amid Fall Surge
- Sophie Monk Launches “100% Wholesome nudie Shots” Campaign, Breaking Engagement Records
- New Frontier Immigration Law Rolls Out National Effort to Assist DACA Professionals with Career-Driven Paths to Permanent Residency
- GoTranscript Launches Multilingual Meeting Bot with 140+ Language Support
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now